PharmAust’s trials of its promising anti-cancer drug in dogs have produced encouraging early results, reducing the size of tumours in three out of four dogs with no other treatment. The early-stage trials have also shown it will be safe to give dogs significantly higher doses, which could lead to some spectacular results in the next stage of trials.
22/05/2017 - 06:16
3 out of 4 dogs reduce cancerous tumour size in PharmAust drug trial
By Matt Birney
22/05/2017 - 06:16
Related Data & Insights
-
-
Rank Company Revenue th PharmAust $842k 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
21 Jun 2024
PharmAust taps investors for $10m
31 May 2024
Shares rise following Thurn return
17 May 2024
Board Moves May 17, 2024
17 May 2024
PharmAust receives FDA approval
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX